Business Wire

OR-GUROBI-OPTIMIZATION

18.8.2020 15:02:14 CEST | Business Wire | Press release

Share
River Logic Selects the Gurobi Optimizer as its Preferred Mathematical Optimization Solver

Gurobi Optimization, LLC and River Logic, Inc today announced that River Logic has chosen the Gurobi Optimizer as the preferred mathematical optimization solver for its prescriptive analytics platform. By embedding the Gurobi Optimizer in its platform, River Logic expects its customers to take full advantage of the capabilities of this best-of-breed solver, leading in many cases to faster solve times and increased profit opportunities.

After a thorough evaluation and selection process, River Logic – which had been using another commercial solver as a component of its prescriptive analytics platform for many years – decided to switch to the Gurobi Optimizer.

River Logic’s Chief Technology Officer Peter Bull said: "We are tremendously excited to announce a long-term partnership with Gurobi to harness the power of their optimization solver technology with River Logic’s unique prescriptive analytics cloud SaaS application. River Logic, now together with Gurobi, is at the forefront of driving prescriptive analytics solutions across an increasing number of industries and organizations, helping them to transform their business operations and capabilities."

There were three main reasons behind River Logic’s decision to switch to the Gurobi Optimizer:

  • Performance : The Gurobi Optimizer is the world’s fastest and most powerful mathematical optimization solver, which is constantly setting new industry standards in terms of speed and solution quality. With the Gurobi Optimizer as a key component of River Logic’s solutions, River Logic customers – many of whom are business users without a background in mathematical programming – will see a substantial reduction in the time it takes to optimally solve complex business problems.
  • Vision : Gurobi’s R&D team – which is comprised of the leading experts in the mathematical optimization software industry – is fully focused on developing and delivering the best mathematical optimization solver technology. This goes hand-in-hand with River Logic’s commitment to providing the best planning and decision-support solutions to its global customers. With Gurobi and River Logic’s commitment to continuous improvement and cutting-edge innovation, River Logic customers can be assured that they are using the state-of-the-art solver – today and in the future.
  • Support : Gurobi’s Support team – which is made up of PhD-level mathematical optimization specialists – is dedicated to providing world-class support for customers using the Gurobi Optimizer. River Logic’s technical team and customers will have access to Gurobi’s Support team – who will be there to assist them and make sure they are able to utilize mathematical optimization as effectively as possible in River Logic’s platform.

Gurobi’s Chief Revenue Officer Duke Perrucci commented: “We are thrilled to have the Gurobi Optimizer power River Logic's suite of first-class optimization applications. Our relentless focus on innovation will allow River Logic's customers to tackle the world's most complex problems at speed and with confidence.”

About Gurobi Optimization

Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability.

As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.

Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit www.gurobi.com or call +1 713 871 9341.

About River Logic

River Logic is on a mission to ensure companies across the globe drive maximum value with every decision, no matter how complex the business problem or how quickly markets shift. As a global innovator in advanced analytics, River Logic offers optimization solutions purpose-built for business users rather than data scientists. Its cloud-based solutions enable enterprise-wide optimization through a revolutionary cloud experience that offers rapid scenario collaboration, data management, workflows, scalability, and more. Companies are finally able to align decisions around complex trade-offs with overarching business objectives without sacrificing speed, agility, and flexibility. For more information, please visit www.riverlogic.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission

KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release

KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige

HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release

The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release

Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release

The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye